InMed Pharmaceuticals (INM) Cash from Investing Activities (2019 - 2024)
InMed Pharmaceuticals (INM) reported Cash from Investing Activities of -$2.0 for Q1 2024, up 100.0% on a YoY basis from -$1.0 in Q2 2023, and up 99.99% quarter-over-quarter from -$33606.0 in Q2 2023.
InMed Pharmaceuticals (INM) Cash from Investing Activities (2019 - 2024) Analysis & Trends
InMed Pharmaceuticals has reported Cash from Investing Activities for 6 years, with the latest figure at -$2.0 in Q1 2024.
- For the quarter ending Q1 2024, Cash from Investing Activities rose 100.0% year-over-year to -$2.0; the trailing twelve-month figure through Jun 2024 stood at -$161806.0 (up 81.84% YoY), and the FY2024 full-year result was -$9293.0, up 98.6% from the prior year.
- Cash from Investing Activities for Q1 2024 stood at -$2.0, up from -$33606.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $306011.0 in Q4 2021, with the low at -$725457.0 in Q2 2022.
- Historically, Cash from Investing Activities has averaged -$93631.9 across 5 years, with a median of -$8800.0 in 2020.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 3508.16% — and 2024, when it surged 100.0%.
- InMed Pharmaceuticals' Cash from Investing Activities stood at $918.0 in 2020, then surged by 33234.53% to $306011.0 in 2021, then tumbled by 337.07% to -$725457.0 in 2022, then jumped by 95.37% to -$33606.0 in 2023, then jumped by 99.99% to -$2.0 in 2024.
- The last three Cash from Investing Activities figures came in at -$2.0 (Q1 2024), -$33606.0 (Q2 2023), and -$128198.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.45 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 25.99 Mn |
| 10 | InMed Pharmaceuticals | 6.04 Mn | 796,124.14 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -2.00 |
| Mar 31, 2024 | -2.00 |
| Jun 30, 2023 | -33,606.00 |
| Jun 30, 2023 | -33,606.00 |
| Mar 31, 2023 | -128,198.00 |
| Mar 31, 2023 | -128,198.00 |
| Jun 30, 2022 | -725,457.00 |
| Jun 30, 2022 | -725,457.00 |
| Mar 31, 2022 | -3,553.00 |
| Mar 31, 2022 | -3,553.00 |
| Dec 31, 2021 | 306,011.00 |
| Dec 31, 2021 | 306,011.00 |
| Sep 30, 2021 | -250,000.00 |
| Sep 30, 2021 | -250,000.00 |
| Jun 30, 2020 | 918.00 |
| Jun 30, 2020 | 918.00 |
| Mar 31, 2020 | -8,800.00 |
| Mar 31, 2020 | -8,800.00 |
| Dec 31, 2019 | 54,912.00 |
| Dec 31, 2019 | 54,912.00 |